Clinical Application of Botulinum Neurotoxin in the Treatment of Myofascial Pain Syndromes

Botulinum Toxin: Therapeutic Clinical Practice and Science

Volumn , Issue , 2009, Pages 283-294

  Childers, Martin K ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82155194090     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4928-9.00023-8     Document Type: Chapter

References (104)

1. Borg-Stein J, Simons DG Focused review: myofascial pain. Arch Phys Med Rehabil 2002, 83(3 suppl 1):S40-S49.
2. Auleciems LM Myofascial pain syndrome: a multidisciplinary approach. Nurse Pract 1995, 20(18):21-28. passim.
3. Windisch A, Reitinger A, Traxler H, Radner H, Neumayer C, Feigl W, et al. Morphology and histochemistry of myogelosis. Clin Anat 1999, 12:266-271.
4. Wallraff J [Histology of myogelosis.]. Munch Med Wochenschr 1951, 93:913-916.
5. Inanici F, Yunus MB History of fibromyalgia: past to present. Curr Pain Headache Rep 2004, 8:369-378.
6. Bengtsson A The muscle in fibromyalgia. Rheumatology 2002, 41:721-724. (Oxford).
7. Schneider MJ Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. J Manipulative Physiol Ther 1995, 18:398-406.
8. Buskila D Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 2001, 13:117-127.
9. Gerwin RD A review of myofascial pain and fibromyalgia-factors that promote their persistence. Acupunct Med 2005, 23:121-134.
10. Goldenberg DL Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 1991, 3:247-258.
11. Henriksson KG Is fibromyalgia a distinct clinical entity? Pain mechanisms in fibromyalgia syndrome. A myologist's view. Baillieres Best Pract Res Clin Rheumatol 1999, 13:455-461.
12. Pongratz DE, Sievers M Fibromyalgia-symptom or diagnosis: a definition of the position. Scand J Rheumatol Suppl 2000, 113:3-7.
13. Gerwin RD Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep 2001, 5:412-420.
14. Escobar PL, Ballesteros J Myofascial pain syndrome. Orthop Rev 1987, 16:708-713.
15. Bohr TW Fibromyalgia syndrome and myofascial pain syndrome. Do they exist?. Neurol Clin 1995, 13:365-384.
16. Fricton JR Myofascial pain syndrome. Neurol Clin 1989, 7:413-427.
17. Simons DG, Mense S [Diagnosis and therapy of myofascial trigger points]. Schmerz 2003, 17:419-424.
18. Aronoff GM Myofascial pain syndrome and fibromyalgia: a critical assessment and alternate view. Clin J Pain 1998, 14:74-85.
19. Buskila D Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 1999, 11:119-126.
20. Mikhail M, Rosen H History and etiology of myofascial pain-dysfunction syndrome. J Prosthet Dent 1980, 44:438-444.
21. Simons DG Myofascial pain syndromes: where are we? Where are we going?. Arch Phys Med Rehabil 1988, 69(3 Pt 1):207-212.
22. Simons DG, Travell JG, Simons LS Myofascial Pain and Dysfunction the Trigger Point Manual 1999, Williams & Wilkins, Baltimore. 2nd.
23. Hsieh CY, Hong CZ, Adams AH, Platt KJ, Danielson CD, Hoehler FK, et al. Interexaminer reliability of the palpation of trigger points in the trunk and lower limb muscles. Arch Phys Med Rehabil 2000, 81:258-264.
24. McPartland JM Travell trigger points-molecular and osteopathic perspectives. J Am Osteopath Assoc 2004, 104:244-249.
25. Mense S, Simons DG, Hoheisel U, Quenzer B Lesions of rat skeletal muscle after local block of acetylcholinesterase and neuromuscular stimulation. J Appl Physiol 2003, 94:2494-2501.
26. Rivner MH The neurophysiology of myofascial pain syndrome. Curr Pain Headache Rep 2001, 5:432-440.
27. Hong CZ, Simons DG Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil 1998, 79:863-872.
28. Macgregor J, Graf von SD Needle electromyographic activity of myofascial trigger points and control sites in equine cleidobrachialis muscle-an observational study. Acupunct Med 2006, 24:61-70.
29. Hong CZ Pathophysiology of myofascial trigger point. J Formos Med Assoc 1996, 95:93-104.
30. Simons DG, Hong CZ, Simons LS Endplate potentials are common to midfiber myofacial trigger points. Am J Phys Med Rehabil 2002, 81:212-222.
31. Ho KY, Tan KH Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review. Eur J Pain 2007, 11:519-527.
32. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006, 67:241-245.
33. Ojala T, Arokoski JP, Partanen J The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain 2006, 22:90-96.
34. Graboski CL, Gray DS, Burnham RS Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005, 118:170-175.
35. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005, 25:604-611.
36. Kuan TS, Chen JT, Chen SM, Chien CH, Hong CZ Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil 2002, 81:512-520.
37. Wheeler AH, Goolkasian P, Gretz SS A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23:1662-1666.
38. Schalow G, Zach GA Reorganization of the human central nervous system. Gen Physiol Biophys 2000, 19(Suppl 1):11-240.
39. Bishop B Spasticity: its physiology and management. Part II. Neurophysiology of spasticity: current concepts. Phys Ther 1977, 57:377-384.
40. Mense S Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004, 251(suppl 1):I1-I7.
41. Sycha T, Kranz G, Auff E, Schnider P Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature. J Neurol 2004, 251(Suppl 1):I19-I30.
42. Ferrante FM, Bearn L, Rothrock R, King L Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005, 103:377-383.
43. Graboski CL, Gray DS, Burnham RS Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005, 118:170-175.
44. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005, 25:604-611.
45. Lang AM A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: a retrospective, open-label chart review. Clin Ther 2003, 25:2268-2278.
46. Ojala T, Arokoski JP, Partanen J The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain 2006, 22:90-96.
47. Porta M A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000, 85:101-105.
48. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006, 67:241-245.
49. Richards BA, Jensen TS A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2007, 68:963-964.
50. Wheeler AH, Goolkasian P, Gretz SS A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23:1662-1666.
51. Graboski CL, Gray DS, Burnham RS Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005, 118:170-275.
52. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006, 67:241-245.
53. Kuan TS, Chen JT, Chen SM, Chien CH, Hong CZ Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil 2002, 81:512-520.
54. Ojala T, Arokoski JP, Partanen J The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain 2006, 22:90-96.
55. Gobel H, Heinze A, Reichel G, Hefter H, Benecke R Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006, 125:82-88.
56. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil 2002, 81:751-759.
57. Papadopoulos EC, Khan SN Piriformis syndrome and low back pain: a new classification and review of the literature. Orthop Clin North Am 2004, 35:65-71.
58. Parziale JR, Hudgins TH, Fishman LM The piriformis syndrome. Am J Orthop 1996, 25:819-823.
59. Dressler D, Saberi FA, Barbosa ER Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005, 63:180-185.
60. Dolly O Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003, 43(suppl 1):S16-S24.
61. Simpson LL Studies on the mechanism of action of botulinum toxin. Adv Cytopharmacol 1979, 3:27-34.
62. Lang AM Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil 2004, 83:198-202.
63. Fishman LM, Zybert PA Electrophysiologic evidence of piriformis syndrome. Arch Phys Med Rehabil 1992, 73:359-364.
64. Aoki KR Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26:785-793.
65. Lucas HJ, Brauch CM, Settas L, Theoharides TC Fibromyalgia-new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 2006, 19:5-10.
66. Gerwin RD, Dommerholt J, Shah JP An expansion of Simons' integrated hypothesis of trigger point formation. Curr Pain Headache Rep 2004, 8:468-475.
67. Shah JP, Phillips TM, Danoff JV, Gerber LH An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol 2005, 99:1977-1984.
68. Burton DJ, Enion D, Shaw DL Pyomyositis of the piriformis muscle in a juvenile. Ann R Coll Surg Engl 2005, 87:W9-W12.
69. Jankiewicz JJ, Hennrikus WL, Houkom JA The appearance of the piriformis muscle syndrome in computed tomography and magnetic resonance imaging. A case report and review of the literature. Clin Orthop Relat Res 1991, 262:205-209.
70. Nakamura H, Seki M, Konishi S, Yamano Y, Takaoka K Piriformis syndrome diagnosed by cauda equina action potentials: report of two cases. Spine 2003, 28:E37-E40.
71. Beatty RA Piriformis syndrome. J Neurosurg Spine 2006, 5:101-102.
72. Beatty RA The piriformis muscle syndrome: a simple diagnostic maneuver. Neurosurgery 1994, 34:512-514.
73. Graff-Radford SB Myofascial pain: diagnosis and management. Curr Pain Headache Rep 2004, 8:463-467.
74. Saravanan P, Dayan CM Thyroid autoantibodies. Endocrinol Metab Clin North Am 2001, 30:315-337. viii.
75. Schussler GC Diagnostic tests and physiological relationships in thyroid disease. Mod Treat 1969, 6:443-464.
76. Fishman LM, Zybert PA Electrophysiologic evidence of piriformis syndrome. Arch Phys Med Rehabil 1992, 73:359-364.
77. Fanucci E, Masala S, Sodani G, Varrucciu V, Romagnoli A, Squillaci E, et al. CT-guided injection of botulinic toxin for percutaneous therapy of piriformis muscle syndrome with preliminary MRI results about denervative process. Eur Radiol 2001, 11:2543-2548.
78. Fishman LM, Konnoth C, Rozner B Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study. Am J Phys Med Rehabil 2004, 83:42-50.
79. Monnier G, Tatu L, Michel F New indications for botulinum toxin in rheumatology. Joint Bone Spine 2006, 73:667-671.
80. Raj PP Botulinum toxin therapy in pain management. Anesthesiol Clin N Am 2003, 21:715-731.
81. Reilich P, Fheodoroff K, Kern U, Mense S, Seddigh S, Wissel J, et al. Consensus statement: botulinum toxin in myofascial [corrected] pain. J Neurol 2004, 251(suppl 1):I36-I38.
82. Harris RE, Clauw DJ The use of complementary medical therapies in the management of myofascial pain disorders. Curr Pain Headache Rep 2002, 6:370-374.
83. Hou CR, Tsai LC, Cheng KF, Chung KC, Hong CZ Immediate effects of various physical therapeutic modalities on cervical myofascial pain and trigger-point sensitivity. Arch Phys Med Rehabil 2002, 83:1406-1414.
84. Hsueh TC, Cheng PT, Kuan TS, Hong CZ The immediate effectiveness of electrical nerve stimulation and electrical muscle stimulation on myofascial trigger points. Am J Phys Med Rehabil 1997, 76:471-476.
85. Graff-Radford SB Regional myofascial pain syndrome and headache: principles of diagnosis and management. Curr Pain Headache Rep 2001, 5:376-381.
86. Wheeler AH Myofascial pain disorders: theory to therapy. Drugs 2004, 64:45-62.
87. McClaflin RR Myofascial pain syndrome. Primary care strategies for early intervention. Postgrad Med 1994, 96:56-59.
88. Nicolakis P, Erdogmus B, Kopf A, Nicolakis M, Piehslinger E, Fialka-Moser V Effectiveness of exercise therapy in patients with myofascial pain dysfunction syndrome. J Oral Rehabil 2002, 29:362-368.
89. Rosen NB Physical medicine and rehabilitation approaches to the management of myofascial pain and fibromyalgia syndromes. Baillieres Clin Rheumatol 1994, 8:881-916.
90. Itoh K, Okada K, Kawakita K A proposed experimental model of myofascial trigger points in human muscle after slow eccentric exercise. Acupunct Med 2004, 22:2-12.
91. Feldman JB The neurobiology of pain, affect and hypnosis. Am J Clin Hypn 2004, 46:187-200.
92. Aronoff GM, Feldman JB, Campion TS Management of chronic pain and control of long-term disability. Occup Med 2000, 15:755-770. iv.
93. Lackner JM, Carosella AM The relative influence of perceived pain control, anxiety, and functional self efficacy on spinal function among patients with chronic low back pain. Spine 1999, 24:2254-2260.
94. Reitsma B, Meijler WJ Pain and patienthood. Clin J Pain 1997, 13:9-21.
95. Jensen MP, Turner JA, Romano JM Changes in beliefs, catastrophizing, and coping are associated with improvement in multidisciplinary pain treatment. J Consult Clin Psychol 2001, 69:655-662.
96. Frost A Diclofenac versus lidocaine as injection therapy in myofascial pain. Scand J Rheumatol 1986, 15:153-156.
97. Arnold LM Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 2006, 8:212.
98. Borg-Stein J Treatment of fibromyalgia, myofascial pain, and related disorders. Phys Med Rehabil Clin N Am 2006, 17:491-510. viii.
99. Rudin NJ Evaluation of treatments for myofascial pain syndrome and fibromyalgia. Curr Pain Headache Rep 2003, 7:433-442.
100. Criscuolo CM Interventional approaches to the management of myofascial pain syndrome. Curr Pain Headache Rep 2001, 5:407-411.
101. Dubbert PM, Carithers T, Sumner AE, Barbour KA, Clark BL, Hall JE, et al. Obesity, physical inactivity, and risk for cardiovascular disease. Am J Med Sci 2002, 324:116-126.
102. Kohl HW Physical activity and cardiovascular disease: evidence for a dose response. Med Sci Sports Exerc 2001, 33(6 suppl):S472-S483.
103. Vitale C, Marazzi G, Volterrani M, Aloisio A, Rosano G, Fini M Metabolic syndrome. Minerva Med 2006, 97:219-929.
104. Warburton DE, Nicol CW, Bredin SS Health benefits of physical activity: the evidence. CMAJ 2006, 14(174):801-809.